Cargando…

Donor bone marrow–derived macrophage MHC II drives neuroinflammation and altered behavior during chronic GVHD in mice

Graft-versus-host disease (GVHD) remains the leading cause of nonrelapse mortality after allogeneic stem cell transplantation for hematological malignancies. Manifestations of GVHD in the central nervous system (CNS) present as neurocognitive dysfunction in up to 60% of patients; however, the mechan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adams, Rachael C., Carter-Cusack, Dylan, Shaikh, Samreen N., Llanes, Genesis T., Johnston, Rebecca L., Quaife-Ryan, Gregory, Boyle, Glen, Koufariotis, Lambros T., Möller, Andreas, Blazar, Bruce R., Vukovic, Jana, MacDonald, Kelli P. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Transplantation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900272/ https://www.ncbi.nlm.nih.gov/pubmed/34570880 http://dx.doi.org/10.1182/blood.2021011671

Ejemplares similares

Third-party type 2 innate lymphoid cells prevent and treat GI tract GvHD
por: Bruce, Danny W., et al.
Publicado: (2021)

Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD
por: Maurer, Katie, et al.
Publicado: (2023)

Chronic GVHD after steroid-sensitive, -dependent, and -refractory acute GVHD: incidence and clinical outcomes
por: Herzog, Shannon, et al.
Publicado: (2023)

Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium
por: DeFilipp, Zachariah, et al.
Publicado: (2021)

PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation
por: Al-Homsi, A. Samer, et al.
Publicado: (2023)

Allodepleted T‐cell immunotherapy after haploidentical haematopoietic stem cell transplantation without severe acute graft‐versus‐host disease (GVHD) in the absence of GVHD prophylaxis
por: Roy, Denis Claude, et al.
Publicado: (2019)

Abatacept GVHD prophylaxis in unrelated hematopoietic cell transplantation for pediatric bone marrow failure
por: Stenger, Elizabeth O., et al.
Publicado: (2023)

Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD
por: Akahoshi, Yu, et al.
Publicado: (2023)

Acute GVHD, BK virus hemorrhagic cystitis and age are risk factors for transplant-associated thrombotic microangiopathy in adults
por: Vasu, Sumithira, et al.
Publicado: (2022)

ICOS immunoPET enables visualization of activated T cells and early diagnosis of murine acute gastrointestinal GvHD
por: Xiao, Zunyu, et al.
Publicado: (2022)

Impact of GVHD prophylaxis on CMV reactivation and disease after HLA-matched peripheral blood stem cell transplantation
por: Ueda Oshima, Masumi, et al.
Publicado: (2023)

Establishment of a predictive model for GVHD-free, relapse-free survival after allogeneic HSCT using ensemble learning
por: Iwasaki, Makoto, et al.
Publicado: (2022)

The day 100 score predicts moderate to severe cGVHD, transplant mortality, and survival after hematopoietic cell transplantation
por: Metafuni, Elisabetta, et al.
Publicado: (2022)

MicroRNA-31 regulates T-cell metabolism via HIF1α and promotes chronic GVHD pathogenesis in mice
por: Wu, Yongxia, et al.
Publicado: (2022)

A novel RIPK1 inhibitor reduces GVHD in mice via a nonimmunosuppressive mechanism that restores intestinal homeostasis
por: Yu, Xiaoliang, et al.
Publicado: (2023)

Mesenchymal stromal cells ameliorate chronic GVHD by boosting thymic regeneration in a CCR9-dependent manner in mice
por: Zhang, Xin, et al.
Publicado: (2023)

Single-cell immune profiling reveals a developmentally distinct CD4(+) GM-CSF(+) T-cell lineage that induces GI tract GVHD
por: Piper, Clint, et al.
Publicado: (2022)

NK cells produce high levels of IL‐10 early after allogeneic stem cell transplantation and suppress development of acute GVHD
por: Chan, Yuen Ling Tracey, et al.
Publicado: (2017)

Inflammasome effects in GvHD
por: Koehn, Brent H., et al.
Publicado: (2015)

EASIX-1year and late mortality after allogeneic stem cell transplantation
por: Kordelas, Lambros, et al.
Publicado: (2023)

Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD
por: Buxbaum, Nataliya P., et al.
Publicado: (2022)

Activation status dictates the function of unlicensed natural killer cells in mice and humans
por: Aguilar, Ethan G., et al.
Publicado: (2021)

MHC Class I Masking to Prevent AMR in a Porcine Kidney Transplantation Model in Alloimmunized Recipients
por: Kervella, Delphine, et al.
Publicado: (2023)

Simultaneous Detection of Circulating Autoreactive CD8(+) T-Cells Specific for Different Islet Cell–Associated Epitopes Using Combinatorial MHC Multimers
por: Velthuis, Jurjen H., et al.
Publicado: (2010)

Induction of Mixed Chimerism With MHC-Mismatched but Not Matched Bone Marrow Transplants Results in Thymic Deletion of Host-Type Autoreactive T-Cells in NOD Mice
por: Racine, Jeremy, et al.
Publicado: (2011)

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study
por: Cutler, Corey, et al.
Publicado: (2021)

Variable CD34(+) recovery of cryopreserved allogeneic HPC products: transplant implications during the COVID-19 pandemic
por: Purtill, Duncan, et al.
Publicado: (2020)

Primary graft failure, but not relapse, may be identified by early chimerism following double cord blood unit transplantation
por: Hough, Rachael, et al.
Publicado: (2022)

Risk of COVID-19 infection in long-term survivors of blood or marrow transplantation: a BMTSS report
por: Johnston, Emily E., et al.
Publicado: (2023)

Increased Effector Memory Insulin-Specific CD4(+) T Cells Correlate With Insulin Autoantibodies in Patients With Recent-Onset Type 1 Diabetes
por: Spanier, Justin A., et al.
Publicado: (2017)

Capture and enrichment of CD34-positive haematopoietic stem and progenitor cells from blood circulation using P-selectin in an implantable device
por: Wojciechowski, Joel C, et al.
Publicado: (2008)

Conversion to sirolimus for chronic renal allograft dysfunction: risk factors for graft loss and severe side effects
por: Abramowicz, Daniel, et al.
Publicado: (2008)

Risk factors for polyoma virus nephropathy
por: Prince, Olivier, et al.
Publicado: (2009)

Benefit of kidney transplantation beyond 70 years of age
por: Heldal, Kristian, et al.
Publicado: (2010)

Pancreas transplantation: differences in activity between Europe and the United States
por: Manuel González-Posada, José, et al.
Publicado: (2009)

Improvement in kidney transplantation in the Balkans after the Istanbul Declaration: where do we stand today?
por: Spasovski, Goce, et al.
Publicado: (2016)

Reciprocating living kidney donor generosity: tax credits, health insurance and an outcomes registry
por: Joshi, Shivam, et al.
Publicado: (2016)

A comparative study of reduced dose alemtuzumab in matched unrelated donor and related donor reduced intensity transplants
por: Jardine, Laura, et al.
Publicado: (2015)

Chronic Renal Transplant Rejection and Possible Anti-Proliferative Drug Targets
por: Bhatti, Adnan Bashir, et al.
Publicado: (2015)

Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease
por: Vickers, Mark A, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_fia9jbmelkcu3e0o4adbn7sp5n